检索结果-南通市图书馆

sTWEAK is a marker of early haematoma growth and leukoaraiosis in intracerebral haemorrhage

Stroke & Vascular Neurology 2021年第4期6卷 528-535,I0011,I0012页

作者： Andrés da Silva-Candal Iria López-Dequidt manuel Rodriguez-Yañez PauloÁvila-Gómez josémanuel pumar joséCastillo Tomás Sobrino Francisco Campos Ramón Iglesias-Rey Pablo Hervella Clinical Neurosciences Research Laboratory(LINC) Health Research Institute of Santiago de Compostela(IDIS)Santiago de CompostelaSpain Department of Neurology Hospital Clínico UniversitarioSantiago de CompostelaSpain Department of Neuroradiology Hospital Clínico UniversitarioSantiago de CompostelaSpain

Objective To study the association between early growth of haematoma with biomarkers of endothelial dysfunction such as leukoaraiosis(LA)and the soluble tumour necrosis factor-like weak inducer of apoptosis(sTWEAK)in patients with intracerebral haemorrhage(ICH).Methods This is a retrospective observational study of patients with nontraumatic *** and biochemical parameters were *** levels were measured by *** was analysed in the hemisphere without haemorrhage to avoid interference with the acute *** main endpoint was the haematoma growth evaluated by the difference in volume between the second and the initial *** functional outcome,defined as a modified Rankin Scale>2 at 3 months,was considered as secondary *** operating characteristic curve analysis was performed to stablish the best cut-off for sTWEAK levels associated with haematoma *** We included 653 patients with ICH in our analysis(71.1±11.9 years,44%women).Haematoma growth was observed in 188 patients(28.8%).sTWEAK levels≥5600 pg/mL predicted ICH growth with a sensitivity of 84%and a specificity of 87%.sTWEAK levels≥5600 pg/mL and the presence of LA were associated with haematoma growth(OR:42.46;(CI 95%22.67 to 79.52)and OR:2.73(CI 95%1.39 to 5.34),respectively).Also,the presence of LA(OR:4.31(CI 95%2.89 to 6.42))and the interaction between ICH growth and sTWEAK(OR:2.23(CI 95%1.40 to 3.55))were associated with poor functional outcome at 3 *** sTWEAKs,together with the presence and grade of LA,are biomarkers able to predict ICH growth and poor functional outcome in patients with ICH.

关键词： TWEAK intracerebral specificity

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Evaluation of ^(177)Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

引用

World Journal of Gastroenterology 2020年第13期26卷 1513-1524页

作者： Estephany Abou Jokh Casas Virginia Pubul Núnez Urbano Anido-Herranz María del Carmen Mallón Araujo Maria del Carmen Pombo Pasín Miguel Garrido pumar josé manuel Cabezas Agrícola josé manuel Cameselle-Teijeiro Ashraf Hilal álvaro Ruibal Morell Department of Nuclear Medicine Santiago de Compostela′s University HospitalSantiago de Compostela 15706A CorunaSpain Department of Oncology Santiago de Compostela′s University HospitalSantiago de Compostela 15706A CorunaSpain Department of Endocrinology Santiago de Compostela′s University HospitalSantiago de Compostela15706A CorunaSpain Department of Pathology Santiago de Compostela′s University HospitalSantiago de Compostela 15706A CorunaSpain Department of Statistics University of Santiago de CompostelaSantiago de Compostela 15706A CorunaSpain

BACKGROUND^177Lu peptide receptor radionuclide therapy(PRRT)is a recently approved therapy in Spain that has been demonstrated to be a well-tolerated therapy for positive somatostatin receptor advanced gastroenteropancreatic neuroendocrine *** To determine the impact of PRRT on quality of life,radiologic and metabolic response,overall survival,prognostic factors and *** Thirty-six patients treated with^177Lu-PRRT from 2016 to 2019 were *** most frequent location of the primary tumor was the gastrointestinal tract(52.8%),pancreas(27.8%),and nongastropancreatic neuroendocrine tumor(11.1%).The liver was the most common site of metastasis(91.7%),followed by distant nodes(50.0%),bone(27.8%),peritoneum(25.0%)and lung(11.1%).Toxicity was evaluated after the administration of each *** efficacywas evaluated by two parameters:stable disease and disease progression in response evaluation criteria in solid tumors 1.1 criterion and prognostic factors were *** From 36 patients,55.6%were men,with a median age of 61.1±11.8 *** previous treatments,55.6%of patients underwent surgery of the primary tumor,100%of patients were treated with long-acting somatostatin analogues,66.7%of patients were treated with everolimus,27.8%of patients were treated with tyrosine kinase inhibitor,and 27.8%of patients were treated with *** patient received radioembolization,three patients received chemoembolization,six patients received *** toxicity was registered in 14 patients(G1-G2:55.5%and G3:3.1%).Other events presented were intestinal suboclusion in 4 cases,cholestasis in 2 cases and carcinoid crisis in 1 *** median follow-up time was 3 ***,24 patients completed *** are alive with stable disease,two have disease progression,eight have died,and nine are still receiving *** median overall survival was 12.5 mo(95%confidence interval range:9.8–15.2),being inversely p

关键词： Peptide receptor radionuclide therapy Gastropancreatic neuroendocrine tumors Radiological response Metabolic response

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：